Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion; Diabetes treatments have improperly listed patents that should be removed, analysis finds

Taking stock of the drug industry, from the lab to the medicine chest

February 5, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Carsten Snejbjerg/Bloomberg STAT+ | Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production The deal could help Novo Nordisk produce more of its wildly popular obesity drug Wegovy, as well as its diabetes medicine Ozempic. By Andrew Joseph STAT+ | Novo's Catalent deal is great for GLP-1s. But what about drug manufacturing? The question is this: Should companies rent access to manufacturing plants or should they own them outright? By Matthew Herper STAT+ | Diabetes treatments have improperly listed patents that should be removed, analysis finds Drugmakers "appear to be using these device patents as part of a strategy to delay competition," said analysis co-author William Feldman. By Ed Silverman Adobe STAT+ | Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down Amgen is testing whether it can wean patients toward lower or less frequent doses of its obesity drug candidate. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser